Samchundang Pharm has signed a term sheet with India's Dr. Reddy's Laboratories to commercialize its long-acting injectable (LAI) platform, targeting a combined market of $5 billion across three complex generic products. The partnership includes co-building a dedicated LAI manufacturing platform in India, with global revenue split 50:50 and Samchundang retaining rights for key Asian markets including South Korea and Japan.
Deal structure and pipeline
The collaboration covers three high-barrier generic injectables: leuprolide depot (a GnRH agonist microsphere for prostate cancer and endometriosis, market $3.4 billion), amphotericin B liposomal injection (antifungal, $700 million), and irinotecan liposomal injection (metastatic pancreatic cancer combination therapy, $900 million). All three are technically challenging to manufacture, creating natural entry barriers.
Manufacturing and revenue model
Dr. Reddy's will contribute its manufacturing infrastructure in Visakhapatnam, India, while Samchundang provides LAI formulation technology, pipeline assets, and strategic marketing rights. The companies will build a shared CMO-style LAI production platform at the Indian site, allowing future products to be added incrementally. Global profits will be split equally, with Samchundang retaining rights for South Korea, Japan, and other key Asian markets.
Timeline and milestones
Samchundang completed the leuprolide depot term sheet in Q2 2025, along with site due diligence at Dr. Reddy's Indian facilities and initial discussions on two liposomal products. The target is to sign definitive agreements by Q3 2025, with technology transfer and regulatory filing preparations expected to begin in 2027.
Strategic context
The LAI platform is one of three strategic pillars Samchundang is advancing in 2025, alongside its oral conversion platform S-PASS and subcutaneous reformulation technology. The company aims to validate LAI through regulatory approvals and technology transfer milestones, positioning it as a key growth driver for overseas partners seeking complex injectable manufacturing capabilities.
What buyers should watch
For distributors and clinic buyers in Asia, Samchundang's retained rights for South Korea and Japan mean these markets will be supplied directly by the Korean partner. Importers in other regions should monitor the 2027 timeline for technology transfer and regulatory submissions, as the partnership's 50:50 profit split suggests competitive pricing potential for these high-demand oncology and antifungal injectables.
Source: Read the original report | Published: June 10, 2026